Our executive team manages the day-to-day operations of our company. Our leaders come from all areas of the business to help position us to succeed. Get to know Merck's Executive team, lead by CEO and president Robert M. Davis.

Kenneth Carleton Frazier (born December 17, 1954) is an American business executive. He is executive chairman and former CEO of the pharmaceutical company Merck & Co. (known as MSD outside of North America). After joining Merck & Co. as general counsel, he directed the company's defense against litigation over the anti-inflammatory drug Vioxx.

Rob Davis is chairman of the board and chief executive officer of Merck. Our executive team manages the strategic direction of the company. Our leaders come from all areas of the business to help position us to succeed.

Since becoming Chair of the Executive Board and CEO of Merck in May 2021, Belén Garijo has led a business transformation to strengthen the company's position as a global science and technology leader.

At Merck, we take on responsibility – including financial responsibility seriously. Members of our Executive Board are personally liable general partners. Get to know our Board of Executives! Chair of the Executive Board and CEO of Merck. Member of the Executive Board | CEO Electronics. Member of the Executive Board | CEO Healthcare.

Apr 12, 2024 · Merck CEO Robert Davis has cracked the $20 million mark in annual pay for the first time, putting him in an exclusive club of biopharma heavy hitters. Davis, 57, who took over …

Jan 14, 2025 · Merck Chairman and CEO Robert Davis joins 'Mad Money' host Jim Cramer at the JPMorgan Healthcare Conference to talk recent acquisitions, growth in its vaccine segment, opportunities in...

Jan 14, 2025 · In an interview on CNBC’s Mad Money, Robert Davis said Merck’s (MRK) current pipeline is the most diversified it has been in recent history. “We’re not just a Keytruda company, we’re an oncology...

Oct 31, 2024 · Merck CEO Robert Davis joins 'Squawk Box' to discuss the company's quarterly earnings results, which topped expectations as the company saw strong sales from its top-selling cancer drug...